CORRECTION FROM SOURCE: Wellgistics Health Secures $50M ELOC Facility for XRP Treasury Reserve and Real-Time Payments Infrastructure and Other General Ops
TAMPA, FL / ACCESS Newswire / May 8, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner.
This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network.
"At Wellgistics Health, we challenge the idea that healthcare has to be tethered to legacy systems, bloated intermediaries, and slow-moving money," said Brian Norton, CEO of Wellgistics Health. "We are developing a platform that connects manufacturers directly to pharmacies and patients-bypassing the red tape and placing control back in the hands of those who deliver care. Our blockchain-enabled payment system and ledger is just the next logical step in healthcare evolution, allowing us to hardwire speed, liquidity, and transparency into a system that's long been starved of all three. I believe that the future winners in healthcare won't be the companies with the biggest buildings…they'll be those with the fastest rails, cleanest data, and most efficient platforms. We're betting on infrastructure…not inertia."
Why XRP? Why Now?
We believe that there are certain advantages to integrating XRP and its related infrastructure into its healthcare ecosystem. These include, among others:
Speed: XRP settles transactions in 3-5 seconds vs. 1-3 days for ACH or wire transfers, allowing for near real-time settlement among pharmacies, suppliers, and manufacturers.Cost: Less than $0.0002 per transfer vs. $10-$30 for standard bank wires.Transparency: All transactions are logged on the XRP Ledger for real-time compliance, rebate tracking, and auditability.Scope: Supports global vendor payouts with significantly low foreign exchange and wire transfer fees.Flexibility: Allows for XRP-backed lines of credit to support independent pharmacy liquidity.
These benefits will support faster vendor payments, performance-based rebates, and embedded liquidity tools for pharmacies and manufacturers in the Wellgistics ecosystem.
Use Cases Across the Ecosystem
Real-time settlement between pharmacies, suppliers, and manufacturersSmart rebates calculated automatically based on real-world dataXRP-backed credit lines to enhance liquidity for independent pharmaciesGlobal vendor payouts with near-zero foreign transaction and wire costsImmutable compliance layer supporting DSCSA reporting and pricing validation
"We're working to unlock capital velocity with surgical precision," said Mark DiSiena, CFO of Wellgistics Health. "We believe that our XRP-powered infrastructure will allow us to run leaner, faster, and with more control than any of our peers in pharma infrastructure."
The Market Is Moving-And Wellgistics Intends to Lead
XRP is gaining momentum across global institutions, as demonstrated by the following:
CME Group to launch XRP futures for institutional access→ CME will launch cash-settled XRP futures contracts in May 2025 to meet rising institutional demand.¹Mastercard identifies XRP as a bridge currency for cross-border payments→ Mastercard's 2025 report highlights XRP as a top solution for global remittances and cost efficiency.²Ripple acquires prime brokerage firm Hidden Road for $1.25B→ This landmark acquisition expands XRP's footprint in institutional liquidity and asset servicing.³Ripple receives regulatory licensing in Dubai→ Ripple became the first blockchain payment provider licensed by the DFSA to operate crypto-based financial services in the UAE.⁴Ripple expands real-world cross-border payment corridors in Brazil and Portugal→ Ripple now enables live XRP-powered remittances between LATAM and Europe through its partnership with Unicâmbio.⁵
"Others are waiting for change. We're building it," Norton added. "I strongly believe that our XRP initiative positions Wellgistics Health years ahead of the curve-and squarely at the center of where healthcare and fintech converge."
About Wellgistics Health
Wellgistics Health, Inc. (NASDAQ:WGRX) is a publicly traded healthcare infrastructure company transforming how medications move, get priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a growing network of more than 6,000 independent pharmacies nationwide.
Wellgistics Health delivers real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment models, while equipping pharmacies with embedded financial, clinical, and digital tools. Its integrated platform supports a wide range of therapeutic categories-from specialty-lite to maintenance meds-by eliminating friction, accelerating reimbursements, and creating direct, transparent pathways between manufacturers, providers, pharmacies, and patients.
For more information, visit: www.wellgisticshealth.com.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at www.sec.gov.
Media Contact: media@wellgisticshealth.comInvestor Relations: investors@wellgisticshealth.com
References
CME Group Press Release: CME to Launch XRP FuturesAInvest: Mastercard Identifies XRP as Bridge CurrencyReuters: Ripple Acquires Hidden Road for $1.25BBusinessWire: Ripple Licensed by DFSA in DubaiPYMNTS: Ripple Launches Portugal-Brazil Corridor
SOURCE: Wellgistics Health, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Nordson Corporation Reports Third Quarter Fiscal 2025 Results and Updates Full Year Guidance
Third Quarter Highlights: Sales were $742 million, an increase of 12% year-over-year Earnings per diluted share were $2.22 Adjusted earnings per diluted share were $2.73, up 13% year-over-year Free cash flow conversion of 180% of net income Board of Directors approved a new $500 million share repurchase authorization WESTLAKE, Ohio, August 20, 2025--(BUSINESS WIRE)--Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal third quarter ended July 31, 2025. Sales were $742 million compared to the prior year's third quarter sales of $662 million. The third quarter 2025 sales included a favorable acquisition impact of 8%, an organic sales increase of 2% and a favorable currency translation impact of 2%. Net income was $126 million, or $2.22 of earnings per diluted share, compared to prior year's third quarter net income of $117 million, or $2.04 of earnings per diluted share. Excluding charges associated with the exit of the medical contract manufacturing business and acquisition-related amortization and costs, third quarter adjusted net income was $155 million versus prior year adjusted net income of $138 million. Third quarter adjusted earnings per diluted share were $2.73, a 13% increase from the prior year adjusted earnings per diluted share of $2.41. EBITDA in the third quarter was $239 million, or 32% of sales, an increase of 15% compared to prior year EBITDA of $208 million, or 31% of sales. Commenting on the Company's fiscal 2025 third quarter results, Nordson President and Chief Executive Officer Sundaram Nagarajan said, "The Nordson team responded effectively to dynamic demand conditions in key end markets and delivered on its promises, realizing solid year-over-year organic growth in the quarter. In particular, the Advanced Technology Solutions segment delivered 15% organic sales growth. Operational excellence drove strong profit performance, increasing adjusted earnings per share by 13% and EBITDA by 15%. In this final full quarter of Atrion's first year acquisition performance, our new employees again exceeded expectations and contributed to both sales and earnings results. Also this quarter, we maintained a strong balance sheet, delivering cash flow conversion of 180% of net income that we used to reduce debt, repurchase shares and return dividends to shareholders, while continuing to invest in the company." Third Quarter Segment Results Industrial Precision Solutions sales of $351 million increased 1% from the prior year, inclusive of an organic sales decrease of 2% and favorable currency translation of 3%. The organic sales decrease was driven by weaker systems demand in polymer processing offsetting growth in most other product lines. Operating profit was $117 million, an increase of $2 million from the prior year. EBITDA in the quarter was $130 million, or 37% of sales, compared to prior year third quarter EBITDA of $131 million, or 37% of sales. Medical and Fluid Solutions sales of $219 million increased 32% compared to the prior year third quarter, inclusive of an acquisition impact of 31% and a favorable currency impact of 1%. Organic sales were flat inclusive of the contract manufacturing business that is held for sale. Excluding the pending divestiture in both periods, organic sales increased 4% driven by medical fluid components and fluid solutions product lines. Operating profit was $53 million, an increase of $4 million from the prior year. Excluding acquisition costs and charges associated with the exit of the medical contract manufacturing business, operating profit was $65 million, an increase of $17 million from the prior year reflecting increased leverage of selling, general and administrative expenses in the core business, as well as contribution from the Atrion acquisition. EBITDA in the quarter was $83 million, or 38% of sales, up 34% versus the prior year third quarter EBITDA of $62 million, or 37% of sales. Advanced Technology Solutions sales of $171 million increased 17% compared to the prior year third quarter, inclusive of an organic sales increase of 15% and favorable currency translation of 3%. The organic sales increase compared to prior year was driven by robust growth in electronics dispense product lines. Operating profit was $37 million, an increase of $11 million due to the strong conversion on increased organic sales. EBITDA in the quarter was $42 million, or 24% of sales, up 35% from the prior year third quarter EBITDA of $31 million, or 21% of sales. Outlook Backlog is down approximately 5% sequentially following a strong third quarter. This supports achieving the Company's original full year sales and earnings guidance, assuming completion of the pending divestiture of the medical contract manufacturing business in the fourth quarter. Fiscal full year sales are now tracking slightly below the mid-point and full year adjusted earnings per share are now tracking slightly above the mid-point of our original guidance. Reflecting on the full year outlook, Nagarajan said, "Following a strong third quarter, I am pleased that we are able to affirm our full year sales guidance and earnings expectations. NBS Next is driving organic growth by enhancing our new product vitality, best-in-class quality and delivery, while also empowering our teams to respond quickly to changing customer demand. Through our close-to-customer business model, diverse product portfolio and in-region, for-region manufacturing strategy, we have continuously demonstrated resilience and the ability to deliver solid growth and best-in-class profitability in varying market scenarios." Nordson management will provide additional commentary on these results and outlook during its previously announced webcast on Thursday, August 21, 2025, at 8:30 a.m. eastern time, which can be accessed at Information about Nordson's investor relations and shareholder services is available from Lara Mahoney, vice president, investor relations and corporate communications at (440) 204-9985 or The Company's definition of adjusted earnings excludes restructuring, business exit and acquisition related cost / amortization for both current and historical periods. It is not possible for the Company to identify the amount or significance of future adjustments associated with acquisition and integration costs, restructuring costs, acquisition-related amortization, certain non-operating or income tax items, or other non-routine costs that the Company adjusts in the presentation of adjusted earnings guidance. These items are dependent on future events that are not reasonably estimable at this time. Accordingly, the Company is unable to reconcile without unreasonable effort the forecasted range of adjusted earnings guidance to a comparable GAAP range. Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as "may," "will," "should," "could," "expects," "anticipates," "believes," "projects," "forecasts," "outlook," "guidance," "continue," "target," or the negative of these terms or comparable terminology. These statements reflect management's current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic and political conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions and the Company's ability to successfully integrate acquisitions; the Company's ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements, including changes in tariffs by the U.S. or other nations; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflicts in Europe and the Middle East, acts of terror, natural disasters and pandemics and the other factors discussed in Item 1A (Risk Factors) in the Company's most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this press release. Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company's direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at linkedin/Nordson, or NORDSON CORPORATION CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (Dollars in thousands except for per-share amounts) Three Months Ended Nine Months Ended July 31, 2025 July 31, 2024 July 31, 2025 July 31, 2024 Sales $ 741,509 $ 661,604 $ 2,039,867 $ 1,945,439 Cost of sales 334,992 292,603 923,550 862,134 Gross profit 406,517 369,001 1,116,317 1,083,305 Gross margin % 54.8 % 55.8 % 54.7 % 55.7 % Selling & administrative expenses 206,539 201,943 606,642 588,196 Divestiture and related charges 12,211 — 12,211 — Operating profit 187,767 167,058 497,464 495,109 Interest expense - net (25,698 ) (17,776 ) (77,335 ) (56,729 ) Other income (expense) - net (2,945 ) 152 (5,380 ) (971 ) Income before income taxes 159,124 149,434 414,749 437,409 Income taxes 33,340 32,107 81,909 92,293 Net income $ 125,784 $ 117,327 $ 332,840 $ 345,116 Weighted-average common shares outstanding: Basic 56,438 57,229 56,784 57,171 Diluted 56,728 57,624 57,084 57,620 Earnings per share: Basic earnings $ 2.23 $ 2.05 $ 5.86 $ 6.04 Diluted earnings $ 2.22 $ 2.04 $ 5.83 $ 5.99 NORDSON CORPORATION CONSOLIDATED BALANCE SHEETS (Unaudited) (Dollars in thousands) July 31, 2025 October 31, 2024 Cash and cash equivalents $ 147,788 $ 115,952 Receivables - net 588,951 594,663 Inventories - net 459,251 476,935 Other current assets 91,275 87,482 Assets held for sale 39,583 — Total current assets 1,326,848 1,275,032 Property, plant and equipment - net 525,604 544,607 Goodwill 3,306,432 3,280,819 Other assets 850,829 900,508 $ 6,009,713 $ 6,000,966 Notes payable and debt due within one year $ 336,078 $ 103,928 Accounts payable and accrued liabilities 436,223 424,549 Liabilities held for sale 10,807 — Total current liabilities 783,108 528,477 Long-term debt 1,785,745 2,101,197 Other liabilities 459,075 439,100 Total shareholders' equity 2,981,785 2,932,192 $ 6,009,713 $ 6,000,966 NORDSON CORPORATION CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) (Dollars in thousands) Nine Months Ended July 31, 2025 July 31, 2024 Cash flows from operating activities: Net income $ 332,840 $ 345,116 Depreciation and amortization 112,454 99,646 Divestiture and related charges 12,211 — Other non-cash items 12,154 15,435 Changes in operating assets and liabilities and other 46,605 (385 ) Net cash provided by operating activities 516,264 459,812 Cash flows from investing activities: Additions to property, plant and equipment (49,002 ) (43,786 ) Other - net 4,272 8,896 Net cash used in investing activities (44,730 ) (34,890 ) Cash flows from financing activities: Repayment of long-term debt - net (94,664 ) (244,355 ) Repayment of finance lease obligations (4,083 ) (4,505 ) Dividends paid (133,008 ) (116,789 ) Issuance of common shares 5,419 29,142 Purchase of treasury shares (218,194 ) (34,105 ) Net cash used in financing activities (444,530 ) (370,612 ) Effect of exchange rate change on cash: 4,832 (4,665 ) Net change in cash and cash equivalents 31,836 49,645 Cash and cash equivalents: Beginning of period 115,952 115,679 End of period $ 147,788 $ 165,324 NORDSON CORPORATION SALES BY GEOGRAPHIC SEGMENT (Unaudited) (Dollars in thousands) Three Months Ended Sales Variance July 31, 2025 July 31, 2024 Organic Acquisitions Currency Total SALES BY SEGMENT Industrial Precision Solutions $ 350,784 $ 348,997 (2.0 )% — % 2.5 % 0.5 % Medical and Fluid Solutions 219,465 166,737 (0.4 )% 31.0 % 1.0 % 31.6 % Advanced Technology Solutions 171,260 145,870 14.6 % — % 2.8 % 17.4 % Total sales $ 741,509 $ 661,604 2.1 % 7.8 % 2.2 % 12.1 % SALES BY GEOGRAPHIC REGION Americas $ 314,568 $ 287,016 (3.2 )% 13.0 % (0.2 )% 9.6 % Europe 186,620 179,370 (6.1 )% 4.8 % 5.3 % 4.0 % Asia Pacific 240,321 195,218 17.4 % 2.9 % 2.8 % 23.1 % Total sales $ 741,509 $ 661,604 2.1 % 7.8 % 2.2 % 12.1 % Nine Months Ended Sales Variance July 31, 2025 July 31, 2024 Organic Acquisitions Currency Total SALES BY SEGMENT Industrial Precision Solutions $ 970,079 $ 1,031,717 (5.7 )% — % (0.3 )% (6.0 )% Medical and Fluid Solutions 615,883 495,229 (7.1 )% 31.5 % — % 24.4 % Advanced Technology Solutions 453,905 418,493 8.0 % — % 0.5 % 8.5 % Total sales $ 2,039,867 $ 1,945,439 (3.1 )% 8.1 % (0.1 )% 4.9 % SALES BY GEOGRAPHIC REGION Americas $ 874,868 $ 855,456 (10.0 )% 13.1 % (0.8 )% 2.3 % Europe 526,878 540,750 (8.7 )% 5.0 % 1.1 % (2.6 )% Asia Pacific 638,121 549,233 13.1 % 3.1 % — % 16.2 % Total sales $ 2,039,867 $ 1,945,439 (3.1 )% 8.1 % (0.1 )% 4.9 % NORDSON CORPORATION RECONCILIATION OF NON-GAAP MEASURES - NET INCOME TO EBITDA (Unaudited) (Dollars in thousands) Three Months Ended Nine Months Ended July 31, 2025 July 31, 2024 July 31, 2025 July 31, 2024 Net income $ 125,784 $ 117,327 $ 332,840 $ 345,116 Income taxes 33,340 32,107 81,909 92,293 Interest expense - net 25,698 17,776 77,335 56,729 Other (income) expense - net 2,945 (152 ) 5,380 971 Depreciation and amortization 37,847 33,382 112,454 99,646 Inventory step-up amortization (1) — — 3,135 2,944 Severance and other (1) 451 2,536 16,725 4,615 Acquisition-related costs (1) 235 5,160 1,778 5,757 Divestiture and related charges (2) 12,211 — 12,211 — EBITDA (non-GAAP) (3) $ 238,511 $ 208,136 $ 643,767 $ 608,071 (1) Represents cost reduction actions as well as fees and non-cash inventory charges associated with acquisitions. (2) Represents asset impairment and other charges associated with the exit of the medical contract manufacturing business. (3) EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as cost reduction actions, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization. NORDSON CORPORATION RECONCILIATION OF NON-GAAP MEASURES - EBITDA (Unaudited) (Dollars in thousands) Three Months Ended Nine Months Ended July 31, 2025 July 31, 2024 July 31, 2025 July 31, 2024 SALES BY SEGMENT Industrial Precision Solutions $ 350,784 $ 348,997 $ 970,079 $ 1,031,717 Medical and Fluid Solutions 219,465 166,737 615,883 495,229 Advanced Technology Solutions 171,260 145,870 453,905 418,493 Total sales $ 741,509 $ 661,604 $ 2,039,867 $ 1,945,439 OPERATING PROFIT Industrial Precision Solutions $ 116,720 $ 115,023 $ 308,153 $ 340,043 Medical and Fluid Solutions 52,500 48,374 150,241 143,467 Advanced Technology Solutions 36,877 26,032 86,558 65,029 Corporate (18,330 ) (22,371 ) (47,488 ) (53,430 ) Total operating profit $ 187,767 $ 167,058 $ 497,464 $ 495,109 OPERATING PROFIT ADJUSTMENTS (1) Industrial Precision Solutions $ — $ 2,536 $ 9,823 $ 6,077 Medical and Fluid Solutions 12,968 — 19,589 — Advanced Technology Solutions (71 ) — 3,217 2,078 Corporate — 5,160 1,220 5,161 Total adjustments $ 12,897 $ 7,696 $ 33,849 $ 13,316 DEPRECIATION & AMORTIZATION Industrial Precision Solutions $ 13,410 $ 13,047 $ 38,477 $ 38,404 Medical and Fluid Solutions 17,685 13,553 54,193 40,822 Advanced Technology Solutions 4,740 4,841 14,058 14,509 Corporate 2,012 1,941 5,726 5,911 Total depreciation & amortization $ 37,847 $ 33,382 $ 112,454 $ 99,646 EBITDA (NON-GAAP) (2) Industrial Precision Solutions $ 130,130 37 % $ 130,606 37 % $ 356,453 37 % $ 384,524 37 % Medical and Fluid Solutions 83,153 38 % 61,927 37 % 224,023 36 % 184,289 37 % Advanced Technology Solutions 41,546 24 % 30,873 21 % 103,833 23 % 81,616 20 % Corporate (16,318 ) (15,270 ) (40,542 ) (42,358 ) Total EBITDA $ 238,511 32 % $ 208,136 31 % $ 643,767 32 % $ 608,071 31 % (1) Represents cost reduction actions, fees and non-cash inventory charges associated with acquisitions, and asset impairment and other charges associated with the exit of the medical contract manufacturing business. (2) EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as cost reduction actions, fees and non-cash inventory charges associated with acquisitions and business exit costs, plus depreciation and amortization. NORDSON CORPORATION RECONCILIATION OF NON-GAAP MEASURES - ADJUSTED NET INCOME AND EARNINGS PER SHARE (Unaudited) (Dollars in thousands) Three Months Ended Nine Months Ended July 31, 2025 July 31, 2024 July 31, 2025 July 31, 2024 GAAP AS REPORTED Operating profit $ 187,767 $ 167,058 $ 497,464 $ 495,109 Other / interest expense - net (28,643 ) (17,624 ) (82,715 ) (57,700 ) Net income 125,784 117,327 332,840 345,116 Diluted earnings per share $ 2.22 $ 2.04 $ 5.83 $ 5.99 Shares outstanding - diluted 56,728 57,624 57,084 57,620 OPERATING PROFIT ADJUSTMENTS Inventory step-up amortization $ — $ — $ 3,135 $ 2,944 Acquisition costs 235 5,160 1,778 5,757 Severance and other 451 2,536 16,725 4,615 Divestiture and related charges 12,211 — 12,211 — ACQUISITION AMORTIZATION OF INTANGIBLES $ 20,092 $ 19,202 59,099 57,412 NON-OPERATING EXPENSE ADJUSTMENTS Entity liquidation $ — $ — $ 988 $ — Total adjustments $ 32,989 $ 26,898 $ 93,936 $ 70,728 Adjustments net of tax $ 29,084 $ 21,134 $ 78,451 $ 55,804 EPS effect of adjustments $ 0.51 $ 0.37 $ 1.37 $ 0.97 NON-GAAP MEASURES-ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE Net income (1) $ 154,868 $ 138,461 $ 411,291 $ 400,920 Diluted earnings per share (2) $ 2.73 $ 2.41 $ 7.20 $ 6.96 (1) Adjusted net income is a non-GAAP measure defined as net income plus tax effected adjustments and other discrete tax items. Refer to the "Reconciliation of Non-GAAP measures - EBITDA" table for definition of adjustments to operating income. (2) Adjusted earnings per share is a non-GAAP measure defined as GAAP EPS adjusted for tax effected adjustments and other discrete tax items. NORDSON CORPORATION RECONCILIATION OF NON-GAAP MEASURES - OPERATING CASH FLOW TO FREE CASH FLOW (Unaudited) (Dollars in thousands) Year to Date July 31, 2025 April 30, 2025 Net cash provided by operating activities $ 516,264 $ 278,292 Additions to property, plant and equipment (49,002 ) (37,439 ) Free Cash Flow - Year to Date (1) $ 467,262 $ 240,853 Free Cash Flow - Quarter to Date (1) $ 226,409 Net Income - Year to Date $ 332,840 $ 345,116 Free Cash Flow Conversion - Year to Date (2) 140 % 70 % Net Income - Quarter to Date $ 125,784 Free Cash Flow Conversion - Quarter to Date (2) 180 % Year to Date July 31, 2024 April 30, 2024 Net cash provided by operating activities $ 459,812 $ 294,964 Additions to property, plant and equipment (43,786 ) (21,907 ) Free Cash Flow - Year to Date (1) $ 416,026 $ 273,057 Free Cash Flow - Quarter to Date (2) $ 142,969 (1) Free Cash Flow is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Net cash provided by operating activities minus Additions to property, plant and equipment. (2) Free Cash Flow Conversion is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Free Cash Flow divided by Net Income. Management uses certain non-GAAP measures, such as adjusted net income, adjusted EPS and EBITDA, internally to make strategic decisions, forecast future results, and evaluate the Company's current performance. Given management's use of these non-GAAP measures, the Company believes these measures are important to investors in understanding the Company's current and future operating results as seen through the eyes of management. In addition, management believes these non-GAAP measures are useful to investors in enabling them to better assess changes in the Company's core business across different time periods. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to other companies' non-GAAP financial measures, even if they have similar names. Amounts may not add due to rounding. View source version on Contacts Lara MahoneyVice President, Investor Relations & Corporate Sign in to access your portfolio
Business Wire
9 minutes ago
- Business Wire
Nordson Corporation Reports Third Quarter Fiscal 2025 Results and Updates Full Year Guidance
WESTLAKE, Ohio--(BUSINESS WIRE)--Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal third quarter ended July 31, 2025. Sales were $742 million compared to the prior year's third quarter sales of $662 million. The third quarter 2025 sales included a favorable acquisition impact of 8%, an organic sales increase of 2% and a favorable currency translation impact of 2%. Net income was $126 million, or $2.22 of earnings per diluted share, compared to prior year's third quarter net income of $117 million, or $2.04 of earnings per diluted share. Excluding charges associated with the exit of the medical contract manufacturing business and acquisition-related amortization and costs, third quarter adjusted net income was $155 million versus prior year adjusted net income of $138 million. Third quarter adjusted earnings per diluted share were $2.73, a 13% increase from the prior year adjusted earnings per diluted share of $2.41. EBITDA in the third quarter was $239 million, or 32% of sales, an increase of 15% compared to prior year EBITDA of $208 million, or 31% of sales. Commenting on the Company's fiscal 2025 third quarter results, Nordson President and Chief Executive Officer Sundaram Nagarajan said, 'The Nordson team responded effectively to dynamic demand conditions in key end markets and delivered on its promises, realizing solid year-over-year organic growth in the quarter. In particular, the Advanced Technology Solutions segment delivered 15% organic sales growth. Operational excellence drove strong profit performance, increasing adjusted earnings per share by 13% and EBITDA by 15%. In this final full quarter of Atrion's first year acquisition performance, our new employees again exceeded expectations and contributed to both sales and earnings results. Also this quarter, we maintained a strong balance sheet, delivering cash flow conversion of 180% of net income that we used to reduce debt, repurchase shares and return dividends to shareholders, while continuing to invest in the company.' Third Quarter Segment Results Industrial Precision Solutions sales of $351 million increased 1% from the prior year, inclusive of an organic sales decrease of 2% and favorable currency translation of 3%. The organic sales decrease was driven by weaker systems demand in polymer processing offsetting growth in most other product lines. Operating profit was $117 million, an increase of $2 million from the prior year. EBITDA in the quarter was $130 million, or 37% of sales, compared to prior year third quarter EBITDA of $131 million, or 37% of sales. Medical and Fluid Solutions sales of $219 million increased 32% compared to the prior year third quarter, inclusive of an acquisition impact of 31% and a favorable currency impact of 1%. Organic sales were flat inclusive of the contract manufacturing business that is held for sale. Excluding the pending divestiture in both periods, organic sales increased 4% driven by medical fluid components and fluid solutions product lines. Operating profit was $53 million, an increase of $4 million from the prior year. Excluding acquisition costs and charges associated with the exit of the medical contract manufacturing business, operating profit was $65 million, an increase of $17 million from the prior year reflecting increased leverage of selling, general and administrative expenses in the core business, as well as contribution from the Atrion acquisition. EBITDA in the quarter was $83 million, or 38% of sales, up 34% versus the prior year third quarter EBITDA of $62 million, or 37% of sales. Advanced Technology Solutions sales of $171 million increased 17% compared to the prior year third quarter, inclusive of an organic sales increase of 15% and favorable currency translation of 3%. The organic sales increase compared to prior year was driven by robust growth in electronics dispense product lines. Operating profit was $37 million, an increase of $11 million due to the strong conversion on increased organic sales. EBITDA in the quarter was $42 million, or 24% of sales, up 35% from the prior year third quarter EBITDA of $31 million, or 21% of sales. Outlook Backlog is down approximately 5% sequentially following a strong third quarter. This supports achieving the Company's original full year sales and earnings guidance, assuming completion of the pending divestiture of the medical contract manufacturing business in the fourth quarter. Fiscal full year sales are now tracking slightly below the mid-point and full year adjusted earnings per share are now tracking slightly above the mid-point of our original guidance. Reflecting on the full year outlook, Nagarajan said, 'Following a strong third quarter, I am pleased that we are able to affirm our full year sales guidance and earnings expectations. NBS Next is driving organic growth by enhancing our new product vitality, best-in-class quality and delivery, while also empowering our teams to respond quickly to changing customer demand. Through our close-to-customer business model, diverse product portfolio and in-region, for-region manufacturing strategy, we have continuously demonstrated resilience and the ability to deliver solid growth and best-in-class profitability in varying market scenarios.' Nordson management will provide additional commentary on these results and outlook during its previously announced webcast on Thursday, August 21, 2025, at 8:30 a.m. eastern time, which can be accessed at Information about Nordson's investor relations and shareholder services is available from Lara Mahoney, vice president, investor relations and corporate communications at (440) 204-9985 or The Company's definition of adjusted earnings excludes restructuring, business exit and acquisition related cost / amortization for both current and historical periods. It is not possible for the Company to identify the amount or significance of future adjustments associated with acquisition and integration costs, restructuring costs, acquisition-related amortization, certain non-operating or income tax items, or other non-routine costs that the Company adjusts in the presentation of adjusted earnings guidance. These items are dependent on future events that are not reasonably estimable at this time. Accordingly, the Company is unable to reconcile without unreasonable effort the forecasted range of adjusted earnings guidance to a comparable GAAP range. Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as 'may,' 'will,' 'should,' 'could,' 'expects,' 'anticipates,' 'believes,' 'projects,' 'forecasts,' 'outlook,' 'guidance,' 'continue,' 'target,' or the negative of these terms or comparable terminology. These statements reflect management's current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic and political conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions and the Company's ability to successfully integrate acquisitions; the Company's ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements, including changes in tariffs by the U.S. or other nations; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflicts in Europe and the Middle East, acts of terror, natural disasters and pandemics and the other factors discussed in Item 1A (Risk Factors) in the Company's most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this press release. Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company's direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at linkedin/Nordson, or NORDSON CORPORATION (Dollars in thousands) October 31, 2024 Cash and cash equivalents $ 147,788 $ 115,952 Receivables - net 588,951 594,663 Inventories - net 459,251 476,935 Other current assets 91,275 87,482 Assets held for sale 39,583 — Total current assets 1,326,848 1,275,032 Property, plant and equipment - net 525,604 544,607 Goodwill 3,306,432 3,280,819 Other assets 850,829 900,508 $ 6,009,713 $ 6,000,966 Notes payable and debt due within one year $ 336,078 $ 103,928 Accounts payable and accrued liabilities 436,223 424,549 Liabilities held for sale 10,807 — Total current liabilities 783,108 528,477 Long-term debt 1,785,745 2,101,197 Other liabilities 459,075 439,100 Total shareholders' equity 2,981,785 2,932,192 $ 6,009,713 $ 6,000,966 Expand NORDSON CORPORATION CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) (Dollars in thousands) Nine Months Ended July 31, 2025 July 31, 2024 Cash flows from operating activities: Net income $ 332,840 $ 345,116 Depreciation and amortization 112,454 99,646 Divestiture and related charges 12,211 — Other non-cash items 12,154 15,435 Changes in operating assets and liabilities and other 46,605 (385 ) Net cash provided by operating activities 516,264 459,812 Cash flows from investing activities: Additions to property, plant and equipment (49,002 ) (43,786 ) Other - net 4,272 8,896 Net cash used in investing activities (44,730 ) (34,890 ) Cash flows from financing activities: Repayment of long-term debt - net (94,664 ) (244,355 ) Repayment of finance lease obligations (4,083 ) (4,505 ) Dividends paid (133,008 ) (116,789 ) Issuance of common shares 5,419 29,142 Purchase of treasury shares (218,194 ) (34,105 ) Net cash used in financing activities (444,530 ) (370,612 ) Effect of exchange rate change on cash: 4,832 (4,665 ) Net change in cash and cash equivalents 31,836 49,645 Cash and cash equivalents: Beginning of period 115,952 115,679 End of period $ 147,788 $ 165,324 Expand NORDSON CORPORATION SALES BY GEOGRAPHIC SEGMENT (Unaudited) (Dollars in thousands) Three Months Ended Sales Variance SALES BY SEGMENT Industrial Precision Solutions $ 350,784 $ 348,997 (2.0 )% — % 2.5 % 0.5 % Medical and Fluid Solutions 219,465 166,737 (0.4 )% 31.0 % 1.0 % 31.6 % Advanced Technology Solutions 171,260 145,870 14.6 % — % 2.8 % 17.4 % Total sales $ 741,509 $ 661,604 2.1 % 7.8 % 2.2 % 12.1 % SALES BY GEOGRAPHIC REGION Americas $ 314,568 $ 287,016 (3.2 )% 13.0 % (0.2 )% 9.6 % Europe 186,620 179,370 (6.1 )% 4.8 % 5.3 % 4.0 % Asia Pacific 240,321 195,218 17.4 % 2.9 % 2.8 % 23.1 % Total sales $ 741,509 $ 661,604 2.1 % 7.8 % 2.2 % 12.1 % SALES BY SEGMENT Industrial Precision Solutions $ 970,079 $ 1,031,717 (5.7 )% — % (0.3 )% (6.0 )% Medical and Fluid Solutions 615,883 495,229 (7.1 )% 31.5 % — % 24.4 % Advanced Technology Solutions 453,905 418,493 8.0 % — % 0.5 % 8.5 % Total sales $ 2,039,867 $ 1,945,439 (3.1 )% 8.1 % (0.1 )% 4.9 % SALES BY GEOGRAPHIC REGION Americas $ 874,868 $ 855,456 (10.0 )% 13.1 % (0.8 )% 2.3 % Europe 526,878 540,750 (8.7 )% 5.0 % 1.1 % (2.6 )% Asia Pacific 638,121 549,233 13.1 % 3.1 % — % 16.2 % Total sales $ 2,039,867 $ 1,945,439 (3.1 )% 8.1 % (0.1 )% 4.9 % Expand NORDSON CORPORATION (Dollars in thousands) Three Months Ended Nine Months Ended July 31, 2025 July 31, 2024 July 31, 2025 July 31, 2024 Net income $ 125,784 $ 117,327 $ 332,840 $ 345,116 Income taxes 33,340 32,107 81,909 92,293 Interest expense - net 25,698 17,776 77,335 56,729 Other (income) expense - net 2,945 (152 ) 5,380 971 Depreciation and amortization 37,847 33,382 112,454 99,646 Inventory step-up amortization (1) — — 3,135 2,944 Severance and other (1) 451 2,536 16,725 4,615 Acquisition-related costs (1) 235 5,160 1,778 5,757 Divestiture and related charges (2) 12,211 — 12,211 — EBITDA (non-GAAP) (3) $ 238,511 $ 208,136 $ 643,767 $ 608,071 Expand (1) Represents cost reduction actions as well as fees and non-cash inventory charges associated with acquisitions. (2) Represents asset impairment and other charges associated with the exit of the medical contract manufacturing business. (3) EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as cost reduction actions, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization. Expand (1) Represents cost reduction actions, fees and non-cash inventory charges associated with acquisitions, and asset impairment and other charges associated with the exit of the medical contract manufacturing business. (2) EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as cost reduction actions, fees and non-cash inventory charges associated with acquisitions and business exit costs, plus depreciation and amortization. Expand (1) Adjusted net income is a non-GAAP measure defined as net income plus tax effected adjustments and other discrete tax items. Refer to the 'Reconciliation of Non-GAAP measures - EBITDA' table for definition of adjustments to operating income. (2) Adjusted earnings per share is a non-GAAP measure defined as GAAP EPS adjusted for tax effected adjustments and other discrete tax items. Expand (1) Free Cash Flow is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Net cash provided by operating activities minus Additions to property, plant and equipment. (2) Free Cash Flow Conversion is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Free Cash Flow divided by Net Income. Expand Management uses certain non-GAAP measures, such as adjusted net income, adjusted EPS and EBITDA, internally to make strategic decisions, forecast future results, and evaluate the Company's current performance. Given management's use of these non-GAAP measures, the Company believes these measures are important to investors in understanding the Company's current and future operating results as seen through the eyes of management. In addition, management believes these non-GAAP measures are useful to investors in enabling them to better assess changes in the Company's core business across different time periods. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to other companies' non-GAAP financial measures, even if they have similar names. Amounts may not add due to rounding.
Wall Street Journal
11 minutes ago
- Wall Street Journal
Tech Stocks Extend Decline, Dragging Indexes Further From Records
A selloff in technology stocks extended into a second day Wednesday, with investors shedding some of the same shares that have powered indexes higher this year. Weakness in the tech sector drove the Nasdaq Composite to a 0.7% decline, bringing its two-day loss to 2.1%. The S&P 500 fell 0.2%, its fourth straight decline, while the Dow Jones Industrial Average edged up less than 0.1%.
